feedback

Course Director

Johanna C. Bendell, MD
Johanna C. Bendell, MD

Sarah Cannon Research Institute
Nashville, Tennessee

Faculty

George P. Kim
George P. Kim, MD

University of Florida Health
Jacksonville, Florida

Eileen M. O'Reilly
Eileen M. O'Reilly, MD

David M. Rubenstein Center for Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jul-05
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The emergence of several novel chemotherapy platforms has opened up new vistas in the management of pancreatic cancer, offering clinicians and patients a wider range of therapeutic choices over multiple lines of therapy and setting the stage for the development of future regimens with innovative components. In this context, selecting the right treatment for the right patient and determining which therapeutic platforms will be most useful as partners for emerging agents—from stroma-targeting drugs to PARP inhibitors and immunotherapies—are some of the key issues for oncology professionals today.

In this PeerView “MasterClass,” based on a recent live symposium in Chicago, Illinois, a panel of experts led by Johanna C. Bendell, MD, explores important topics such as therapy selection and sequencing, adverse event management, and the clinical potential of novel agent classes (including the use of clinical trials as a management option). Throughout this MasterClass, our experts also feature voices and views from patients with pancreatic cancer (brought to you via a collaboration with Let’s Win!, an affiliate of the Lustgarten Foundation).

Upon completion of this activity, participants should be better able to:
  • Discuss recent efficacy and safety evidence related to approved and emerging treatment options for pancreatic cancer
  • Apply effective strategies for therapy selection, sequencing, and adverse event management associated with approved treatment options for advanced pancreatic cancer
  • Summarize ongoing clinical trials investigating novel cytotoxics, immunotherapies, other targeted agents, or combinations of agents, for patients with pancreatic cancer in a range of disease settings
  • Advise patients with pancreatic cancer on safe and effective individualized treatment plans that reflect optimal patient-centric selection and sequencing of therapeutic options

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with pancreatic cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 5, 2018 - July 4, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Johanna C. Bendell, MD
Chief Development Officer
Director, GI Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Johanna C. Bendell, MD, has no financial interests/relationships or affiliations in relation to this activity.
Johanna C. Bendell, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: novel targeted and immune therapies for the treatment of pancreatic cancer, including cytotoxic agents, PARP inhibitors, stromal modifying agents, and checkpoint inhibitors.

Faculty

George P. Kim, MD
Member, U.S. Intergroup Pancreas Cancer Task Force
Consultant, University of Florida Health
Jacksonville, Florida

George P. Kim, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation and Ipsen.
Speakers Bureau participant with Celgene Corporation and Ipsen.
George P. Kim, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: novel targeted and immune therapies for the treatment of pancreatic cancer, including cytotoxic agents, PARP inhibitors, stromal modifying agents, and checkpoint inhibitors.

Eileen M. O'Reilly, MD
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Eileen M. O'Reilly, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Agios, Inc.; Amgen Inc.; Antengene Corporation; Aptus Clinical; Aslan Pharmaceuticals; Astellas Pharma US, Inc.; AstraZeneca; Bayer Corporation; Boston Scientific Corporation; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals Inc.; Celgene Corporation; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Debiopharm Group; Delcath Systems Inc.; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Onxeo; PCI Biotech; sanofi-aventis U.S. LLC; Servier; Silenseed LTD; Sillajen; Sirtex SIR - Spheres Pty Ltd.; Vicus Therapeutics; and Yakult Pharmaceutical Industry Co., Ltd.
Grant/Research Support from Agios, Inc.; Array BioPharma; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; CASI Pharmaceuticals Inc.; Celgene Corporation; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Incyte Corporation; Eli Lilly and Company; MabVax Therapeutics Holdings, Inc.; MedImmune; Momenta Pharmaceuticals; Novartis Pharmaceuticals Corporation; and OncoMed Pharmaceuticals, Inc.
Eileen M. O’Reilly, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: novel targeted and immune therapies for the treatment of pancreatic cancer, including cytotoxic agents, PARP inhibitors, stromal modifying agents, and checkpoint inhibitors.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Celgene Corporation, Halozyme Therapeutics, and Ipsen Biopharmaceuticals, Inc.

Collaboration Statement


This CME activity has been developed in collaboration with Let’s Win!, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win! is an affiliate of the Lustgarten Foundation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.